Rucaparib or Physician's Choice in Metastatic Prostate Cancer
Por um escritor misterioso
Descrição
NEJMστο X: Original Article: Rucaparib or Physician's Choice in Metastatic Prostate Cancer (TRITON3) #GU23 #oncology / X
ASCO GU 2023: Rucaparib for Metastatic Castration-Resistant Prostate Cancer (mCRPC): TRITON3 Interim Overall Survival and Efficacy of Rucaparib vs Docetaxel or Second-Generation Androgen Pathway Inhibitor Therapy
Pathways involved in natural progression of prostate cancer
TRITON-3 Validates Rucaparib Monotherapy After a Prior ARPI but Before Chemotherapy in BRCA-Mutated mCRPC
Cancers, Free Full-Text
Cancers, Free Full-Text
PARP Inhibitors - Effective in Men with BRCA-Mutant Prostate Cancer - CancerConnect
TRITON3 Rucaparib vs Physician's Choice of Single-Agent Therapy in Metastatic Castration-Resistant Prostate Cancer With BRCA or ATM Alterations - The ASCO Post
The TRITON3 Study for mCRPC: Rucaparib or Physician's Choice?
Novel therapies are changing treatment paradigms in metastatic prostate cancer, Journal of Hematology & Oncology
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Cancers, Free Full-Text
de
por adulto (o preço varia de acordo com o tamanho do grupo)
